Analgesic Effect of Etoricoxib (ARCOXIA®) 120MG During Retinal Laser Photocoagulation
Overview
The study wants to show if the medication etoricoxib 120 mg have reduces the patients pain during the laser photocoagulation, for diabetic retinopathy.
Full Title of Study: “Analgesic Effect of Etoricoxib (ARCOXIA®) 120MG During Retinal Laser Photocoagulation”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Primary Purpose: Treatment
- Masking: Triple (Participant, Care Provider, Investigator)
Detailed Description
To do so we compare two group of patients, randomized 1:1, one use the medication(etoricoxib) and other use placebo and they quantify the pain using the Pain visual analogue scale
Interventions
- Drug: placebo (Control Group)
- Both medication have been given to the patients in both groups 1 hour prior the laser photocoagulation
- Drug: Etoricoxib (Treatment Group)
- Both medication have been given to the patients in both groups 1 hour prior the laser photocoagulation
Arms, Groups and Cohorts
- Placebo Comparator: Control Group
- Patients who received placebo
- Active Comparator: Treatment Group
- Patients who received etoricoxib 120 mg
Clinical Trial Outcome Measures
Primary Measures
- The group taking the etoricoxib feel less pain then the group taking placebo
- Time Frame: After each laser session
Participating in This Clinical Trial
Inclusion Criteria
- Patients with diabetic retinopathy that needs laser photocoagulation for the first time Exclusion Criteria:
- Younger than 17 – Signs and symptoms of liver dysfunction or abnormal liver function tests – Gastrointestinal diseases – Pregnant women – Edema – Pre-existing cardiac insufficiency
Gender Eligibility: All
Minimum Age: 17 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- University of Sao Paulo
- Overall Official(s)
- Vinicius P Nascimento, MD, Principal Investigator, Clinica Oftalmologica do Hospital das Clinicas da Universidade de São Paulo
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.